Eritoran Tetrasodium
| Code | Size | Price |
|---|
| TAR-T27281-5mg | 5mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Eritoran Tetrasodium, a TLR4 receptor antagonist, is used potentially for the treatment of type 2 diabetes.
CAS:
185954-98-7
Formula:
C66H122N2Na4O19P2
Molecular Weight:
1401.604
Purity:
0.98
SMILES:
[Na+].[Na+].[Na+].[Na+].CCCCCCCCCCCC(=O)CC(=O)NC1C(OP([O-])([O-])=O)OC(COC2OC(COC)C(OP([O-])([O-])=O)C(OCCC(CCCCCCC)OC)C2NC(=O)CCCCCCCCCC=C/CCCCCC)C(O)C1OCCCCCCCCCC
References
1. Mcdonald KA, Huang H, Tohme S, Loughran P, Ferrero K, Billiar T, Tsung A. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling. Mol Med. 2015 Mar 13;20:639-48. doi: 10.2119/molmed.2014.00076. PubMed PMID: 25375408; PubMed Central PMCID: PMC4365061.
2. Kuo WT, Lee TC, Yu LC. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That Bind Lipopolysaccharide. Cancer Res. 2016 Aug 15;76(16):4684-95. doi: 10.1158/0008-5472.CAN-16-0172. PubMed PMID: 27328732.
3. Korff S, Loughran P, Cai C, Lee YS, Scott M, Billiar TR. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma. J Surg Res. 2013 Oct;184(2):e17-25. doi: 10.1016/j.jss.2013.03.023. PubMed PMID: 23777984.
4. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL; ACCESS Study Group.. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013 Mar 20;309(11):1154-62. doi: 10.1001/jama.2013.2194. PubMed PMID: 23512062.